Regulation between LRRK2 and PP2A signaling in cellular models of Parkinsons disease

This study elucidates a reciprocal regulatory mechanism in Parkinson's disease where PP2A dephosphorylates LRRK2 to reduce its kinase activity, while LRRK2 phosphorylates the PP2A subunit PPP2CA at T304 to impair holoenzyme formation, a disruption that exacerbates LRRK2-G2019S-induced neuronal death.

The Gist

The Big Picture: A Broken Brake and a Jammed Gearbox

Imagine your brain is a busy city. In this city, there are delivery trucks (neurons) that need to move smoothly to keep the city running. In Parkinson's disease, these trucks start breaking down and dying, causing traffic jams and chaos.

Two main characters are involved in this story:

1. LRRK2: Think of this as the Engine of the delivery truck. In healthy people, the engine runs at a steady, controlled speed. But in Parkinson's patients (especially those with a specific genetic mutation called G2019S), this engine gets stuck in "High Gear." It revs way too fast, overheating the truck and causing it to break down.
2. PP2A: Think of this as the Brake System. Its job is to slow things down, keep the engine cool, and ensure the truck doesn't crash.

For a long time, scientists knew that if you could fix the Engine (LRRK2) or strengthen the Brakes (PP2A), you could save the trucks. But they didn't know exactly how these two parts talked to each other.

This paper reveals a fascinating, two-way conversation between the Engine and the Brakes that goes wrong in Parkinson's disease.

---

Part 1: The Brake System Tries to Fix the Engine

The Discovery: The researchers found that the Brake System (PP2A) can actually reach into the Engine (LRRK2) and press a specific "reset button" (a chemical tag called a phosphate group) located at a spot called T1503.

• The Analogy: Imagine the Engine has a sticky gear. When the gear is sticky (phosphorylated), the Engine clamps together tightly into a double-unit (a dimer) and spins out of control, revving dangerously fast.
• What PP2A does: The Brake System (PP2A) acts like a mechanic with a solvent. It sprays the sticky gear, cleaning off the gunk (removing the phosphate).
• The Result: Once the gunk is gone, the Engine unclamps. It stops spinning as a dangerous double-unit and slows down to a safe speed.
• The Proof: When the scientists added more Brake System (PP2A) to cells, the Engine slowed down. When they blocked the Brake System, the Engine went crazy.

Part 2: The Engine Sabotages the Brakes

The Twist: You might think the story ends there: "Brakes fix Engine." But the researchers found something surprising. The Engine (LRRK2) is so powerful that it fights back.

• The Discovery: When the Engine is running too fast (hyperactive), it reaches out and grabs the Brake System (PP2A) itself. It applies a chemical "lock" to a critical part of the brake pedal called T304.
• The Analogy: Imagine the Engine is so hot and aggressive that it grabs the brake pedal and jams it with a piece of gum (the phosphate group).
• The Consequence: This jamming prevents the Brake System from assembling correctly. The brake pads can't connect to the brake disc. The whole braking mechanism falls apart.
• The Result: The Engine not only runs too fast, but it also actively destroys the very thing that is supposed to stop it. It's a vicious cycle: The faster the Engine runs, the more it breaks the Brakes, which makes the Engine run even faster.

Part 3: The "Methylation" Mystery (The Glue)

To make the Brake System work, it needs a special type of glue (methylation) to hold all its parts together.

• When the Engine jams the Brake at spot T304, it causes the glue to dissolve.
• Without the glue, the Brake System falls apart and becomes useless.
• The researchers found that in Parkinson's patients, this "glue" is missing, which explains why the brakes fail even if the brake parts are still there.

Part 4: Saving the Neurons

The most exciting part of the study happened in the lab with living brain cells (neurons).

• The Experiment: They took brain cells that were being killed by the "Hyperactive Engine" (G2019S-LRRK2).
• The Fix: When they added a healthy, normal Brake System (Wild-Type PP2A), the cells survived! The brakes worked, the engine slowed down, and the cells were saved.
• The Failure: However, when they tried to add a Brake System that had been "jammed" by the Engine (the T304 mutant), it failed to save the cells. The jammed brakes couldn't stop the crash.

Why This Matters

This paper changes how we think about treating Parkinson's.

1. It's a Two-Way Street: We can't just look at the Engine (LRRK2) or just the Brakes (PP2A). We have to look at how they fight each other.
2. New Treatment Ideas: Instead of just trying to slow down the Engine, we might be able to treat Parkinson's by strengthening the Brakes. If we can prevent the Engine from jamming the Brake pedal (perhaps by protecting that T304 spot), we could stop the cycle of destruction.
3. Broader Impact: Since this "jamming" mechanism seems to happen in other types of Parkinson's (even without the genetic mutation), fixing this communication loop could help a much larger group of patients.

In short: Parkinson's disease involves a runaway engine that not only speeds up on its own but also actively breaks its own brakes. The key to fixing the car might be to repair the brakes so they can't be jammed, allowing them to finally slow the engine down.

Technical Summary

1. Problem Statement

Parkinson's disease (PD) is the second most common neurodegenerative disorder. Mutations in Leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial PD, and increased LRRK2 kinase activity is also observed in idiopathic (sporadic) PD. While LRRK2 is known to be regulated by phosphorylation (autophosphorylation and heterophosphorylation) and dephosphorylation, the specific molecular mechanisms governing its activation cycle and the role of phosphatases in the RocCOR-GTPase domain remain unclear.

Specifically, the study addresses two critical gaps:

1. How does Protein Phosphatase 2A (PP2A) regulate LRRK2 kinase activity and dimerization?
2. Is there a reciprocal regulatory loop where LRRK2 phosphorylates PP2A, potentially impairing PP2A function in PD?

2. Methodology

The authors employed a multi-faceted approach combining in vitro biochemistry, cell biology, and primary neuronal models:

• Protein Purification & In Vitro Assays:

  • Recombinant human LRRK2 RocCOR domain and full-length LRRK2 were purified.
  • Kinase Assays: Used Dictyostelium Roco4 kinase to phosphorylate LRRK2 RocCOR. Used purified LRRK2 to phosphorylate PP2A catalytic subunit (PPP2CA).
  • Phosphatase Assays: Incubated phosphorylated LRRK2 with purified PPP2CA to test dephosphorylation. Measured PP2A phosphatase activity using phosphopeptide substrates.
  • Mass Spectrometry: Used Data-Independent Acquisition (DIA) and targeted PRM to identify specific phosphorylation sites (T1503 on LRRK2 and T304 on PPP2CA).

• Cellular Models:

  • HEK293T Cells: Used for overexpression studies, proximity biotinylation assays to isolate LRRK2 dimers, and co-immunoprecipitation (Co-IP) to study protein-protein interactions.
  • A549 Lung Carcinoma & RAW264.7 Macrophages: Used to study endogenous LRRK2 activation. Cells were treated with Zymosan (to activate LRRK2) or Okadaic Acid (PP2A inhibitor) and MLi-2 (LRRK2 inhibitor).
  • Primary Mouse Cortical Neurons: Used to assess neurotoxicity. Neurons were transfected with G2019S-LRRK2 (PD mutant) co-expressed with Wild-Type (WT) or mutant PPP2CA. Cell death was quantified via Caspase-3 activation and immunofluorescence.

• Key Techniques:

  • Proximity Biotinylation: To specifically isolate and quantify LRRK2 dimers.
  • Western Blotting & Dot-blotting: Using specific antibodies (pT1503-LRRK2, pThrPro for PPP2CA-T304, methyl-PP2A-C).
  • Mutagenesis: Creation of phospho-dead (T1503A, T304A) and phospho-mimetic (T304D) mutants.

3. Key Contributions & Results

A. PP2A Dephosphorylates LRRK2 at T1503, Reducing Activity

• Identification: The study identified Threonine 1503 (T1503) within the LRRK2 Roc domain as a specific substrate for PP2A.
• Mechanism: In vitro and cellular data showed that PP2A dephosphorylates T1503.
• Functional Consequence:
  • Dephosphorylation of T1503 leads to the destabilization of LRRK2 dimers.
  • Reduced dimerization correlates with a significant decrease in LRRK2 kinase activity.
  • The phospho-dead mutant T1503A mimics the effect of PP2A overexpression: it forms unstable dimers and exhibits reduced kinase activity.

B. LRRK2 Phosphorylates PP2A at T304, Impairing PP2A Function

• Reciprocal Regulation: The study discovered that LRRK2 phosphorylates the catalytic subunit of PP2A (PPP2CA) at Threonine 304 (T304).
• Impact on Methylation: Phosphorylation at T304 (a Thr-Pro site) alters the methylation status of the C-terminal Leucine 309 (L309). Methylation is crucial for PP2A holoenzyme assembly.
• Holoenzyme Disruption:
  • Phosphorylation (or phospho-mimicry T304D) prevents the binding of PPP2CA to regulatory B subunits (specifically PPP2R2B/B55β and PPP2R5C/B56γ).
  • This leads to the dissociation of the PP2A holoenzyme.
• Loss of Activity: Both phospho-mimetic (T304D) and phospho-dead (T304A) mutants of PPP2CA showed reduced phosphatase activity compared to WT, indicating that the precise regulation of T304 is critical for PP2A function.

C. Neuroprotection Requires Intact PP2A Regulation

• Rescue Experiment: Overexpression of WT-PPP2CA protected primary cortical neurons from G2019S-LRRK2-induced cell death.
• Failure of Mutants: PPP2CA mutants (T304A and T304D) failed to protect neurons from LRRK2 toxicity.
• Conclusion: The ability of PP2A to protect against LRRK2 toxicity depends on the proper regulation of the T304 residue, which ensures holoenzyme formation and catalytic activity.

D. Relevance to Idiopathic PD

• The study notes that in $\alpha$-synuclein models and post-mortem PD brain tissue, PP2A activity is downregulated, and methylation is decreased. This mirrors the effect of hyperactive mutant LRRK2, suggesting a convergent pathological mechanism where impaired PP2A function exacerbates PD pathology.

4. Significance

This paper establishes a bidirectional regulatory loop between LRRK2 and PP2A, which is central to Parkinson's disease pathogenesis:

1. PP2A as a Brake: PP2A acts as a negative regulator of LRRK2 by dephosphorylating T1503, destabilizing dimers, and reducing kinase activity.
2. LRRK2 as a Saboteur: Hyperactive LRRK2 (as seen in PD mutants) phosphorylates PP2A at T304. This modification disrupts PP2A holoenzyme assembly and methylation, effectively "sabotaging" the phosphatase that normally keeps LRRK2 in check.
3. Therapeutic Implications:
   • The findings suggest that boosting PP2A activity (e.g., by stabilizing holoenzyme formation or enhancing methylation) could be a viable therapeutic strategy for both familial (LRRK2-mutant) and idiopathic PD.
   • It highlights the C-terminal methylation status of PPP2CA as a critical biomarker and potential drug target.

In summary, the study elucidates a molecular feedback loop where LRRK2 and PP2A mutually regulate each other's activity and stability, and the disruption of this loop contributes significantly to neuronal death in Parkinson's disease.